Brief: Nabriva Therapeutics Granted New Technology Add-On Payment For Xenleta And Contepo
10/09/2020 14:36
Sept 10 (Reuters) - Nabriva Therapeutics PLC NBRV.O :
* NABRIVA THERAPEUTICS GRANTED NEW TECHNOLOGY ADD-ON PAYMENT
FOR
XENLETA® (LEFAMULIN) AND CONTEPO™ (FOSFOMYCIN) BY CENTERS FOR
MEDICARE & MEDICAID SERVICES
* NABRIVA - FROM OCTOBER 1, CMS TO GIVE ADDITIONAL MAXIMUM
PAYMENT
OF $1,275.75 FOR XENLETA WHEN USED IN INPATIENT HOSPITAL SETTING
FOR FISCAL YEAR 2021
* NABRIVA THERAPEUTICS PLC - IV AND ORAL FORMULATIONS OF
XENLETA
WERE GRANTED QUALIFIED INFECTIOUS DISEASE PRODUCT AND FAST TRACK
DESIGNATION BY FDA
Source text for Eikon: ID:nGNXbZgz8w
Further company coverage: NBRV.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nabriva Therapeutics
See all newsBrief: Nabriva Therapeutics And Units Enter Asset Purchase Agreement With Sumitomo Pharma
Brief: Nabriva Therapeutics Says Received Delisting Determination Letter From Nasdaq
Brief: Nabriva Therapeutics Receives Notice Of Delisting Or Failure To Satisfy Continued Listing Rule From Nasdaq
Brief: Nabriva Therapeutics - On Jan 31, Co's Unit Entered Into Letter Agreement With 2 Units Of Merck & Co, About Distribution Agreement, Dated July 15, 2020
Brief: Nabriva Therapeutics Provides Corporate Update